You will see a Seeking Alpha note by Istvan on Yahoo Finance page of OGXI. Really good read with high level overview of where 5 different drugs fit in prostate cancer space. Very positive notes about OGXI and 011; he actually states he may start long position in OGXI!
"If the drug can show that it is effective in reducing docetaxel resistance, it may have a huge market. Additionally, clusterin is found in tumors from numerous other cancers including breast, ovarian, bladder and non-small cell lung, making for a potential market expanding way beyond prostate cancer. With a market cap of just $122 million, OncoGeneX is a risk, but has the potential for huge upside. If approved, OncoGeneX would have Teva’s global reach behind them, providing an advantage for marketing and distribution.
Disclosure: I have no positions in any stocks mentioned, but may initiate a long position in OGXI, TEVA over the next 72 hours."